glp-1/gip dual agonist weight loss Why does GLP‐1 combined with GIP and/or GCG agonist have greater effect than GLP‐1 agonist alone in obese adults without type 2 diabetes? - Jiang - 2025 Frontiers | Effect of dual

Sterne JAC, Savovi J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials

In the trials, participants who took the highest dose reduced their A1C values by an average of 2.0%

These results established tirzepatide as the most potent agent in the current pharmacologic armamentarium for obesity

Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial

Gastric sleeve may be a good fit for patients without severe reflux, while gastric bypass may be preferred for patients with significant reflux, diabetes, or revision needs